📑REACTIVO PARA DOSIFICACION DE CICLOSPORINA, REACTIVO PARA DETECCION DE ANTICUERPO ANTI-TIROGLOBULINA (TGB), REACTIVO PARA DETECCION DE ANTICUERPO ANTI-CITOMEGALOVIRUS (CMV) IGM
Procurement process summary
This process is to purchase Reactivo para dosificacion de ciclosporina, reactivo para deteccion de anticuerpo anti-tiroglobulina (tgb), reactivo para deteccion de anticuerpo anti-citomegalovirus (cmv) igm.
This contract was awarded by 🇺🇾 Hospital Maciel for an amount of UYU 202,185 to 1 supplier. It was published on 2025-10-08 through not reported
Transparency in this process is reflected in the detailed publication of all aspects of the contract and its results.
Buying entity🇺🇾 Hospital Maciel Buying unitnot reported Publication date2025-10-08 Contest statusnot reported Descriptionnot reportedAwards
This award was granted to BIOERIX SA by Hospital Maciel for an amount of UYU 202,185. The procurement process was conducted through Not available for the category of Not available. The award was granted on 2025-10-08.
| Supplier | Amount | Award date |
|---|---|---|
| 🇺🇾 BIOERIX SA | UYU 202,185 | 2025-10-08 |
Market context and opportunities
The execution of this contract allows the entity Hospital Maciel to fulfill its public service objectives efficiently.
Transparency in this process is reflected in the detailed publication of all aspects of the contract and its results.
This transparency in public procurement promotes fair competition, prevents corruption, and ensures that public resources are used efficiently for the benefit of citizens.
Additional data
Contract NumberUY_ocds-yfs5dr-1283533-R213168300014Publication date2025-10-08Contract datenot reportedAward date2025-10-08Categoriesnot reportedPurchase modalitynot reportedMethod detailsnot reportedStatusnot reportedData sources
Sociedad.info publishes data from official sources, in compliance with public information access laws. Public access to this data is a civic right that helps hold government accountable. This data, including names and identifiers, is already public in the official source. Read our privacy policy.
